Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Imprimis Pharmaceuticals has now secured the complete exclusive US commercial rights to the patented compounded alkalinized lidocaine and heparin formulation (Hep-Lido-A) for the treatment of interstitial cystitis (IC).
Subscribe to our email newsletter
IC, commonly referred to as painful bladder syndrome (PBS), is a chronic disease characterized by bladder pressure, bladder pain, urinary urgency and/or urinary frequency. It affects an estimated ten million men and women in the US alone with women making up 80% of those affected.
In April 2015, Imprimis provided formal notice to Urigen of its intent to convert its commercial rights of Hep-Lido-A to exclusive for the remaining term of the agreement.
Imprimis CEO Mark Baum said: "In 2014, physicians wrote more than 80,000 prescriptions of Hep-Lido-A, generating an estimated $5.5m in sales.
"In due course, we plan to capture substantially all of these legacy prescriptions, and have already begun sales to existing prescribers for their chronic care patients.
"Over the last several months, we have been busy building relationships with IC thought leaders and new physician customers.
"We are recruiting a team of seasoned urology sales and marketing professionals with experience and relationships in the IC community to lead our commercial activities."
The company was granted the non-exclusive US licensing rights for Hep-Lido-A from Urigen Pharmaceuticals in October 2014.
As part of the license deal, Imprimis had the option to convert to an exclusive license between the six-month and one-year anniversary period from the date of the agreement.